All In Biotech

Drug Trial Radar · NCT07088458

An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia A

An Observational Study Describing Real-World Treatment Outcomes of Damoctocog Alfa Pegol in Patients Aged 7 to <12 Years With Hemophilia A

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 16, 2026

Primary completion

Dec 31, 2029

Study completion Mar 1, 2030

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 7 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational study of children with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol, and are between 7 to \<12 years of age at the time of enrolment. Observational studies use data that are collected as part of routine medical care and participants do not receive any advice or any changes to healthcare as part of the study. In this study, the data will be collected from participants who are starting or already receiving damoctocog alfa pegol as prescribed by their doctor. Participants taking part may have received factor 8 (FVIII) treatment before. The study may also include participants who have never received factor 8 treatment or who have received it only a few times. Hemophilia A is a genetic bleeding disorder. It is caused by the lack of a protein called clotting factor 8 (FVIII) that helps blood to clot properly. Lack of FVIII can result in excessive blood loss or bleeding inside the body after being injured or having surgery. At times, there is spontaneous bleeding into the joint spaces that leads to joint damage. The drug observed in this study, damoctocog alfa pegol, is approved for doctors to prescribe to children who are at least 7 years old with hemophilia A. It is used to prevent or treat bleeding episodes and works by replacing missing FVIII in the body of people with hemophilia A. The participants will receive damoctocog alfa pegol as prescribed independently by their own doctors during routine practice, not as a part of the study. Participants may choose to enroll in the study at any time after their doctor has prescribed damoctocog alfa pegol to prevent bleeding episodes. The main purpose of this study is to learn more about how a treatment with damoctocog alfa pegol works to prevent bleeding episodes in routine medical practice. To answer this question, doctors will collect: * information about bleeding episodes including the type and the location of the bleed * information about the treatment with damoctocog alfa pegol and other FVIII products * the overall health status of the participants Data will be collected from participants over two years after they enroll in the study or until they choose to leave the study or switch to another hemophilia A treatment. Historical data will come from the participants' medical records or by interviewing the patient and parent/ legal guardian. The children's parents/ guardians will be asked to maintain a health diary to record details of bleeding episodes and treatment with damoctocog alfa pegol. The children's parents/ guardians will also be asked to answer a questionnaire (PedHAL) to assess the effect of hemophilia on their child's functional and physical activities. In this study, only available data from routine care will be collected. No additional visits or tests are required as part of this study.

Conditions

  • Hemophilia A

Interventions

  • Damoctocog alfa pegol (Jivi, Bay94-9027)Drug

    Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treated bleeds per individual diary documentation period while prescribed damoctocog alfa pegol prophylaxis (overall and by dosing regimen)Time frame: Up to 24 months

Locations

12 sites in 11 countries. Site status is shown where the registry gives one.

  • Loma Linda University Health

    Loma Linda, California · Not yet recruiting

  • Rutgers, The State University

    New Brunswick, New Jersey · Not yet recruiting

  • Many locations

    Many Locations, Brazil · Not yet recruiting

  • Many locations

    Many Locations, Canada · Withdrawn

  • Many locations

    Many Locations, Colombia · Not yet recruiting

  • Many locations

    Many Locations, Denmark · Not yet recruiting

  • Many locations

    Many Locations, Italy · Not yet recruiting

  • Many locations

    Many Locations, Japan · Not yet recruiting

  • Many locations

    Many Locations, Lithuania · Recruiting

  • Many locations

    Many Locations, Mexico · Not yet recruiting

  • Many locations

    Many Locations, Norway · Not yet recruiting

  • Many locations

    Many Locations, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.